METHOD FOR INDUCING DIFFERENTIATION INTO CARDIOMYOCYTES USING G-CSF

• US 20110129922A1
• Filed: 06/06/2008
• Published: 06/02/2011
• Est. Priority Date: 06/07/2007
• Status: Active Grant

• Current Assignee: Keiichi Fukuda
• Original Assignee: Keiichi Fukuda
• Inventors: Fukuda, Keiichi, Shimoji, Kenichiro, Yuasa, Shinsuke
• Granted Patent: US 8,252,583 B2
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

A method for inducing differentiation of ES cells into cardiomyocytes, which comprises contacting the ES cells with an agonist for G-CSF receptor.

Claims

1. A method for inducing differentiation of ES cells into cardiomyocytes, which comprises contacting the ES cells with an agonist for G-CSF receptor.

2. The method according to claim 1, which comprises culturing the ES cells in the presence of the agonist for G-CSF receptor.

3. The method according to claim 1, wherein the agonist for G-CSF receptor is G-CSF.

4. The method according to claim 3, which comprises the following steps:

(a) adding the G-CSF to a cell culture solution; and

(b) culturing the ES cells using the culture solution from step (a).

5. The method according to claim 4, wherein the ES cells and the G-CSF are contacted in vitro.

6. The method according to claim 1, which further comprises the step of culturing the ES cells in the presence of a substance that inhibits BMP signaling, prior to contacting the ES cells with the agonist for G-CSF receptor.

7. The method according to claim 6, wherein the substance that inhibits BMP signaling is Noggin.

8. Cardiomyocytes obtained by the method according to claim 1.

9. An inducer of cardiomyocyte differentiation from ES cells, which comprises an agonist for G-CSF receptor.

10. The inducer of cardiomyocyte differentiation according to claim 9, wherein the agonist for G-CSF receptor is G-CSF.

11. The inducer of cardiomyocyte differentiation according to claim 9, which is used in vitro.

12-15. -15. (canceled)

16. A method for producing cardiomyocytes, which comprises contacting ES cells with an agonist for G-CSF receptor.

17. The method according to claim 16, which comprises culturing the ES cells in the presence of the agonist for G-CSF receptor.

18. The method according to claim 17, wherein the agonist for G-CSF receptor is G-CSF.

19. The method according to claim 16, which comprises the following steps:

(a) adding the G-CSF to a cell culture solution; and

(b) culturing the ES cells using the culture solution from step (a).

20. The method according to claim 19, wherein the ES cells and the G-CSF are contacted in vitro.

21. The method according to claim 16, which further comprises the step of culturing the ES cells in the presence of a substance that inhibits BMP signaling, prior to contacting the ES cells with the agonist for G-CSF receptor.

22. The method according to claim 21, wherein the substance that inhibits BMP signaling is Noggin.